Dexcom (NSDQ:DXCM) said today it will incorporate ambulatory glucose profile data into its web-based Clarity software.
The Clarity software is designed to provide access to clinically relevant data, metrics and reports for diabetes management and care, the San Diego-based company said.
“I hope that utilizing the AGP to standardize CGM metrics and the glucose profile display will help clinicians and patients together to formulate a personalized action plan to optimize glucose control,” Dr. Richard Bergenstal of St. Louis Park, Minn.’s International Diabetes Center said in a prepared release.
Ambulatory glucose profile reports were developed by the International Diabetes Center and includes a summary of patient glucose data in a statistical summary, visual display and daily views, Dexcom said. The data can be used as a platform to inform patients and clinicians on trends and patterns related to their care.
“AGP reports have been used for several years by physicians and presents the most relevant statistical and graphical information that would allow clinicians to quickly assess the glucose control of a patient and make meaningful clinical decisions. By having a wider adoption of this report by medical device companies, it allows the information to be agnostic to the manufacturer. AGP can become the EKG report of diabetology – where there is one standard glucose report that all clinicians can interpret,” Dr. George Grunberger of Bloomfield Hills, Mich.’s Grunberger Diabetes Institute said in prepared remarks.
“Dexcom is pleased to partner with the IDC in implementing a standard report across all platforms – allowing physicians and health care professionals to compare information in a consistent format. As the industry leader in continuous glucose monitoring, it is important that we align with industry recommendations and clinical societies to provide the tools and information needed to help clinicians improve clinic work flow while managing their patients’ diabetes with glucose data and reporting,” prez & CEO Kevin Sayer said in a preapred statement.
Yesterday, Dexcom said it won FDA approval for its G5 mobile app for Android devices, allowing users to view and monitor their glucose levels on their Android devices in real time.